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Background:  Annual  seasonal  inﬂuenza  vaccination  is  recommended  for  transplant  recipients.  No  formal
pharmacoepidemiology  study  has  been  published  on the association  between  solid  organ  transplant
(SOT)  rejection  and  vaccination  with  seasonal  trivalent  inactivated  inﬂuenza  vaccines  (TIIVs).
Methods:  The  risk  of  SOT  (liver,  kidney,  lung,  heart  or  pancreas)  rejection  after  TIIV  vaccination  was
assessed  using  a self-controlled  case-series  method  (NCT01715792).  SOT  recipients  in  England  with  trans-
plant rejection  were  selected  from  the  Clinical  Practice  Research  Datalink  and  linked  Hospital  Episode
Statistics  inpatient  data.  The  study period  (September  2006  to August  2009)  encompassed  three  con-
secutive  inﬂuenza  seasons.  We  calculated  the  relative  incidence  (RI)  of SOT  rejection  between  the  30-
and  60-day  post-vaccination  risk  periods  and  the control  periods  (any  follow-up  period  excluding  risk
periods),  using  a Poisson  regression  model.
Results:  In  seasons  2006/07,  2007/08,  2008/09  and  pooled  seasons,  132,  136,  168  and  375  subjects,  respec-
tively,  experienced  at least  one  transplant  rejection;  approximately  half  (45%–51%)  of these subjects  had
received  a  TIIV.  For  season  2006/07,  the RI of  rejection  of any  organ,  adjusted  for time  since  transplan-
tation,  was 0.74  (95%  CI: 0.24–2.28)  and  0.58  (95%  CI: 0.24–1.38)  during  the  30-day  and  60-day  risk
periods, respectively.  Corresponding  RIs  for season  2007/08  were  1.21  (95%  CI: 0.55–2.64) and  1.31  (95%
CI:  0.69–2.48);  for season  2008/09,  0.99  (95%  CI: 0.43–2.28)  and  0.64  (95%  CI:  0.31–1.33); and  for  pooled
seasons  1.01  (95%  CI:  0.58–1.76)  and  0.88  (95%  CI: 0.56–1.38).  The  results  of  a separate  analysis  of kidney
rejections  and  analyses  that  took  into  account  additional  potential  confounders  were  consistent  with
those  of the  main  analyses,  with  95%  CIs  including  1 and  upper  limits  below  3.
Conclusion:  This  study  provides  reassuring  evidence  of  the  safety  proﬁle  of  TIIVs  in  SOT  recipients,  thus
mensupporting  current  recom
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1. Introduction
Compared to the general population, individuals with a com-
promised immune system are at increased risk of medical
complications following inﬂuenza virus infection [1]. Solid organ
transplant (SOT) recipients are a notable high-risk immuno-
suppressed population [2]. Inﬂuenza virus infection can cause
substantial morbidity and mortality in SOT recipients and can
trigger acute rejection and chronic allograft dysfunction [3–7]. Con-
sequently, annual seasonal inﬂuenza vaccination is recommended
for transplant recipients and their close contacts as an important
preventative health measure [8].
Although inﬂuenza vaccination is generally well tolerated in
SOT recipients [9], there is a paucity of robust and conclusive
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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vidence regarding the risk of acute cellular and humoral rejection
pisodes or allograft dysfunction following inﬂuenza vaccination
1,2,4]. Several spontaneous case reports in the published litera-
ure have suggested a possible association between SOT rejection
r early signs of rejection among transplant recipients who had
eceived inﬂuenza vaccination during the 2009 H1N1 pandemic
nﬂuenza [10–12]. One case of pancreas rejection was reported
nd a small case-control study identiﬁed six cases of short-term
ellular rejection among heart transplant recipients shortly fol-
owing receipt of pandemic inﬂuenza vaccination during the 2009
1N1 pandemic [10,11]. De novo anti-HLA antibodies were found
n kidney transplant recipients who had received both seasonal and
andemic inﬂuenza immunization [12].
In view of these spontaneous case reports and following spo-
adic post-marketing surveillance reports of SOT rejection after
eceipt of GSK’s monovalent AS03 (Adjuvant System contain-
ng -tocopherol and squalene in an o/w emulsion) adjuvanted
009 H1N1 pandemic vaccine (PandemrixTM, GSK Vaccines, Wavre,
elgium), a post-authorization safety study (PASS) was requested
y the European Medicines Agency to assess the risk of SOT rejec-
ion following vaccination with PandemrixTM in the 2009/2010
andemic inﬂuenza season. These results have been reported else-
here [13]. An additional objective of this study, which is the
ubject of the present manuscript, was to assess the risk of SOT
ejection after immunization with seasonal trivalent inactivated
nﬂuenza vaccines (TIIVs). Although annually-updated TIIVs have
een routinely administered to SOT recipients for several years,
o formal pharmacoepidemiology study of their use had been con-
ucted in this patient group. In this study, the risk of organ rejection
fter vaccination with TIIVs was assessed among SOT recipients
ho experienced a transplant rejection in England during three
onsecutive inﬂuenza seasons.
. Methods
In this retrospective, observational database study (ClinicalTri-
ls.gov, NCT01715792), we assessed the risk of SOT (liver, kidney,
ung, heart or pancreas) rejection within 30 and 60 days follow-
ng the receipt of TIIVs using the self-controlled case-series (SCCS)
ethod. This statistical case-only method compares the incidence
ate of an event during predeﬁned risk and control periods within
 given individual, thereby controlling for individual level con-
ounding factors that do not vary over time [14]. The study period
panned from 1 September 2006 to 31 August 2009, encompass-
ng three consecutive inﬂuenza seasons (2006/07, 2007/08 and
008/09).
The Clinical Practice Research Datalink (CPRD), an observa-
ional and interventional research service that operates as part
f the UK Department of Health, contains over 4 million active
atient records (over 11 million overall) drawn from approxi-
ately 675 primary care practices in the UK [15,16]. The population
f active patients represents 7% of the total UK population, and
PRD patients have been shown to be representative of the
K general population in terms of age, sex and ethnicity [16].
he CPRD has been granted Multiple Research Ethics Commit-
ee approval (05/MRE04/87) to undertake purely observational
tudies, with external data linkages including Hospital Episode
tatistics (HES) and Ofﬁce for National Statistics mortality data.
he work of CPRD is also covered by the National Information
overnance Board for Health and Social Care’s Ethics and Conﬁ-
entiality Committee approval ECC 5-05 (a) 2012. This study was
ndorsed by the Independent Scientiﬁc Advisory Committee for
edicines and Healthcare products Regulatory Agency database
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2.1. Subjects and data collection
Cases were identiﬁed from patients registered in general prac-
tices contributing to the CPRD and with a linked HES inpatient
component [17–19] using pre-deﬁned algorithms. The CPRD con-
tains coded longitudinal medical records from general practices in
the UK [17] and the HES inpatient database contains details of all
admissions to National Health Service (NHS) hospitals in England
[19,20]. HES inpatient data linkage is limited to CPRD research-
acceptable patients with a valid NHS number, living in England and
who belong to a general practice that has agreed to take part in data
linkage.
Subjects were eligible for this study if they received a liver, kid-
ney, lung, heart or pancreas transplant and experienced at least
one episode of transplant rejection during the study period. Sub-
jects were deﬁned as acceptable for research by the CPRD if they
had no follow-up interruptions and information on year of birth,
ﬁrst registration date and gender, and if the data were considered
to be of good quality, according to data quality assessments per-
formed by the CPRD team [16]. The study dataset was  built using
the 2012 third quarter CPRD release, which compiled information
from 10,547,532 subjects, with a mean follow-up of 6.8 years, from
644 general practices.
Records of transplantation and transplant rejection events were
identiﬁed using pre-deﬁned algorithms based on READ codes in
the CPRD and ICD-10 clinical and OPCS-4 procedural codes in the
HES linked component (Supplementary Table 1). Multiple trans-
plant rejection episodes for a single individual were considered
as new only if they occurred at least 30 days after the previous
record of transplant rejection, apart from heart rejections, for which
all episodes were considered as distinct events. A transplantation
episode in an individual was  considered as new if reported by OPCS-
4 procedural codes or if it occurred more than 14 days since the
previous transplant episode.
CPRD code lists for inﬂuenza vaccination were developed by
querying the CPRD database for relevant product and inﬂuenza
immunization terms and by using British National Formulary
therapy group 14040900 (Supplementary Table 2). The inﬂuenza
virus strains included in the licensed TIIVs were based on the
annual World Health Organization (WHO) recommendations for
the Northern Hemisphere [21]. Information on the TIIV brands
administered was  available for only 10%, 20% and 12% in each of
the seasons 2006/07, 2007/08 and 2008/09, respectively.
In order to obtain additional quantitative and qualita-
tive information on identiﬁed cases, a standard questionnaire
(Supplementary Text 1) was sent to general practitioners (GPs) via
the CPRD Research Group in October 2012.
2.2. Statistical analyses
Sample size was  estimated for the primary objective of the study
(i.e., to assess the risk of SOT rejection following vaccination with
PandemrixTM in the 2009/2010 pandemic inﬂuenza season) using
relevant information and deﬁned assumptions based on feasibility
data (Supplementary Text 2). We  found that, with 30 cases, there
was 80% power to detect a relative incidence (RI) of 3 or higher. The
association between SOT rejection and seasonal vaccination with
TIIVs was  assessed by calculating the RI of SOT rejection between
the 30-day and 60-day post-vaccination risk periods and the con-
trol periods, with associated 95% conﬁdence intervals (CIs). The
30-day risk period was  deﬁned a priori, based on the observed
latency period of spontaneous rejection events reported to GSK’s
Global Clinical Safety and Pharmacovigilance among subjects who
had received PandemrixTM and the most common risk period fol-
lowing other exposures such as infection [3]. The case series model
is derived from a Poisson cohort model by conditioning on the total
3 ccine 34 (2016) 3598–3606
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Fig. 1. SOT rejections and TIIV exposure in each 15-day period between 1 September
2006 and 31 August 2007 (A), 1 September 2007 and 31 August 2008 (B), and 1600 G. Dos Santos et al. / Va
umber of events and on the exposures that are experienced by
ach individual in the cohort over a predetermined observation
eriod [22].
Risk periods covered the 30-day or 60-day period after vacci-
ation with TIIVs; the control period corresponded to any period
f the study follow-up, excluding risk periods. Since rejection was
ikely to inﬂuence the probability of subsequent vaccination, a mod-
ﬁed SCCS method was used, which was developed for situations
here occurrence of the event could curtail post-event exposures
14]. The modiﬁed SCCS method required subjects to have only
ne SOT rejection; consequently, only the ﬁrst SOT rejection was
ncluded for each subject and subjects were censored for further
ejections. Because censoring at subsequent rejections may  not be
ptimal and to verify the robustness of our results, we  performed
 sensitivity analysis using the standard SCCS method [23,24] in
hich subjects were not censored at subsequent rejections.
Separate analyses were conducted for each inﬂuenza season.
 pooled analysis of the three seasons was also conducted and
tatistical methods are described in Supplementary Text 3. Sub-
ects with a complete follow-up, starting at least 180 days before
 September of at least one season, were included in the anal-
ses. The 180-day period was required to accumulate sufﬁcient
istorical data for subjects. This was to determine if risk periods
tarting before the analysis period overlapped it, for instance, risk
eriod 91–180 days after transplantation, when transplantation
appened within 180 days before the analysis period. Based on
 feasibility assessment in the CPRD, we found that the risk of
ransplant rejection was high within the ﬁrst month following the
ransplantation, then declined substantially up to three months
nd reached its lowest level around six months, with a stable
ncidence from six months onwards. Because time since transplan-
ation was considered an independent risk factor for SOT rejection,
he analyses were adjusted for time since transplantation (risk peri-
ds 0–30, 31–90, 91–180 and >180 days) and included additional
IIV-unexposed subjects to better account for the effect of this
ovariate [24]. Supplementary Fig. 1 illustrates the circumstances
n which cases were regarded as informative or non-informative
or the main analyses. Additional covariates, i.e. bacterial infections,
hronic viral infections and cancer/malignancies (risk periods 0–30,
–365 and 0–365 days, respectively), considered to be indepen-
ent risk factors for SOT rejection [25], were added to the model
rovided that information was available for at least ﬁve subjects.
ince covariate data could also originate from TIIV-unexposed sub-
ects, when covariates were added, subjects could potentially be
dded to the model. Sensitivity analyses were performed focus-
ng on organ-speciﬁc data and history of rejection. The effect of
revious rejection within 180 days before 1 September of each
eason on the risk of subsequent rejection could not be investi-
ated because of insufﬁcient sample size (fewer than ﬁve subjects).
 separate analysis was performed including only subjects without
revious rejection within 180 days before the start of the sea-
on.
Analyses and data extraction were performed using SAS soft-
are version 9.2.
. Results
.1. Study population and TIIV exposureA total of 132, 136 and 168 subjects had at least one transplant
ejection in seasons 2006/07, 2007/08 and 2008/09, respectively,
f whom approximately half (45.4%, 49.3% and 50.6%, respectively)
ad received a TIIV. The distribution of SOT rejections and exposure
o TIIV during each season is shown in Fig. 1.September 2008 and 31 August 2009 (C) in subjects with at least one SOT rejection.
SOT, solid organ transplantation; TIIV, trivalent inactivated inﬂuenza vaccine.
The demographic characteristics of subjects were similar across
seasons (Table 1). Most subjects (90.2%, 89.7% and 90.5% in
2006/07, 2007/08 and 2008/09, respectively) were followed from
1 September to 31 August. The remaining subjects either died or
G. Dos Santos et al. / Vaccine 34 (2016) 3598–3606 3601
Table  1
Demographic characteristics of subjects included in study populations for inﬂuenza seasons 2006/07, 2007/08 and 2008/09. All had at least one SOT rejection reported in the
Health  Episodes Statistics database and follow-up included 1 September.
Season 2006/07 Season 2007/08 Season 2008/09
Unexposed
to TIIV
(N = 72)
Exposed to
TIIV
(N = 60)
Total
(N = 132)
Unexposed
to TIIV
(N = 69)
Exposed to
TIIV (N
=67)
Total
(N = 136)
Unexposed
to TIIV
(N = 83)
Exposed to
TIIV
(N = 85)
Total
(N = 168)
Age at beginning of seasona, years
Mean (standard
deviation)
43.0 (16.7) 54.2 (18.8) 48.1 (18.5) 42.4 (18.0) 52.6 (17.3) 47.4 (18.3) 45.2 (17.9) 51.6 (17.4) 48.4 (17.9)
Range  5–77 6–90 5–90 1–75 9–87 1–87 1–82 6–88 1–88
Female, n (%) 28 (38.9) 22 (36.7) 50 (37.9) 22 (31.9) 31 (46.3) 53 (39.0) 36 (43.4) 35 (41.2) 71 (42.3)
Time  since transplantation at beginning of season, n (%)
0–30 days 1 (1.4) 0 1 (0.8) 1 (1.4) 0 1 (0.7) 0 0 0
31–90  days 2 (2.8) 2 (3.3) 4 (3.0) 2 (2.9) 4 (6.0) 6 (4.4) 1 (1.2) 0 1 (0.6)
91–180  days 0 0 0 1 (1.4) 2 (3.0) 3 (2.2) 0 6 (7.1) 6 (3.6)
>180  days or before
transplantation
69 (95.8) 58 (96.7) 127 (96.2) 65 (94.2) 61 (91.0) 126 (92.6) 82 (98.8) 79 (92.9) 161 (95.8)
Organ  transplant rejection during season, n (%)
Kidney 29 (40.3) 39 (65.0) 68 (51.5) 39 (56.5) 43 (64.2) 82 (60.3) 41 (49.4) 57 (67.1) 98 (58.3)
Liver  8 (11.1) 4 (6.7) 12 (9.1) 4 (5.8) 1 (1.5) 5 (3.7) 8 (9.6) 8 (9.4) 16 (9.5)
Lung  3 (4.2) 2 (3.3) 5 (3.8) 0 (0) 1 (1.5) 1 (0.7) 1 (1.2) 3 (3.5) 4 (2.4)
Heart  3 (4.2) 3 (5.0) 6 (4.5) 3 (4.3) 5 (7.5) 8 (5.9) 3 (3.6) 3 (3.5) 6 (3.6)
Pancreas 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.5) 1 (0.7) 0 (0) 0 (0) 0 (0)
Kidney and liver 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.5) 1 (0.7) 0 (0) 0 (0) 0 (0)
Heart  and lung 0 (0) 1 (1.7) 1 (0.8) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.2) 1 (0.6)
Unspeciﬁedb 29 (40.3) 11 (18.3) 40 (30.3) 23 (33.3) 15 (22.4) 38 (27.9) 30 (36.1) 13 (15.3) 43 (25.6)
≥1  transplant rejection
episode before
season of interestc, n
(%)
5 (6.9) 9 (15.0) 14 (10.6) 9 (13.0) 6 (9.0) 15 (11.0) 8 (9.6) 14 (16.5) 22 (13.1)
Number of organ transplantations received during season, n (%)
0  57 (79.2) 46 (76.7) 103 (78.0) 54 (78.3) 56 (83.6) 110 (80.9) 67 (80.7) 68 (80.0) 135 (80.4)
1  11 (15.3) 13 (21.7) 24 (18.2) 14 (20.3) 9 (13.4) 23 (16.9) 15 (18.1) 13 (15.3) 28 (16.7)
2  4 (5.6) 1 (1.7) 5 (3.8) 1 (1.4) 2 (3.0) 3 (2.2) 1 (1.2) 4 (4.7) 5 (3.0)
Subjects reporting
cancer/malignanciesd,
n (%)
4 (5.6) 5 (8.3) 9 (6.8) 4 (5.8) 6 (9.0) 10 (7.4) 4 (4.8) 6 (7.1) 10 (6.0)
Reasons for end of follow-up other than end of season, n (%)
Died 3 (4.2) 6 (10.0) 9 (6.8) 3 (4.3) 8 (11.9) 11 (8.1) 6 (7.2) 6 (7.1) 12 (7.1)
End  of CPRD
follow-up
3 (4.2) 1 (1.7) 4 (3.0) 2 (2.9) 1 (1.5) 3 (2.2) 3 (3.6) 1 (1.2) 4 (2.4)
CPRD, Clinical Practice Research Datalink; SOT, solid organ transplant; TIIV, trivalent inactivated inﬂuenza vaccine.
a Season started 1 September 2006, 2007 or 2008 and ended 31 August 2007, 2008 or 2009.
b The code for transplant rejection was  a general code without any organ speciﬁed.
c 180-day period before start of season.
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ed Incidence of cancer/malignancies was recorded (for season 2006/07) during 1
ugust 2008 and (for season 2008/09) between 1 September 2007 and 31 August 2
ere no longer followed in the CPRD because they had left the
eneral practice or the practice was no longer active in the CPRD.
ost subjects had records of transplantation or rejection for a sin-
le organ (130 in 2006/07, 128 in 2007/08 and 163 in 2008/09).
he most common organ transplant rejection was  kidney rejection
Table 1).
The characteristics and number of subjects included in the
ooled seasonal analyses are presented in Table 2. A total of 375
ubjects were considered eligible of whom 175 were exposed to a
IIV. Most subjects received their transplant more than 6 months
efore the study start. A majority of cases experienced kidney rejec-
ions (>60%) and few subjects presented with cancers/malignancies
6.7%).
GP questionnaires were returned for only 140 of 587 (23.9%)
ubjects with a record of transplant rejection in the CPRD during
he period of interest. Transplant rejection events appeared to be
nder-reported and under-documented, with GPs reporting less
han 40% of the number of rejections initially identiﬁed in the CPRD.
nformation reported on other covariates of interest or compliance
o treatment was also very limited. Consequently, the HES inpatient
atabase was  used as the sole data source for transplant rejection
pisodes.y period before season, (for season 2007/08) between 1 September 2006 and, 31
3.2. Risk of SOT rejection following vaccination with a TIIV
3.2.1. Model adjusted for time since transplantation
The study population for the 2006/07 season consisted of 132
subjects who had experienced at least one SOT rejection between
1 September 2006 and 31 August 2007. In that season, one subject
had received two TIIV doses and was  excluded, leaving 131 sub-
jects for the analysis (Fig. 2). 58 subjects were excluded because
they were not informative for the analysis (subjects did not receive
TIIV during the analysis period from 1 September to 31 August or
they received TIIV only before transplantation during the analysis
period). Thus the analyses adjusted for time since transplantation
included 74 cases, of whom 55 had received a TIIV; 19 additional
unexposed cases were included to better account for the effect of
time since transplantation. For season 2007/08, 81 subjects con-
tributed to the analyses; 58 cases had received a TIIV and 23 were
unexposed cases. For season 2008/09, 92 subjects contributed to
the analyses, of whom 72 were TIIV-exposed and 20 were unex-
posed cases. Pooling the three consecutive seasons, 375 subjects
experienced at least one transplant rejection, of whom 218 were
included in the analyses adjusted for time since transplantation
and of whom 156 received a TIIV (Figs. 3 and 4).
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Table  2
Demographic characteristics of subjects included in the study population for pooled seasonal inﬂuenza analysis. All had at least one SOT rejection reported in the Health
Episodes Statistics database and follow-up included 1 September. Each subject contributed to only one season, the ﬁrst with an exposure to TIIV or with an effect of time
since  transplantation.
Unexposed to TIIV (N = 200) Exposed to TIIV (N =175) Total (N = 375)
Age at beginning of analyzed seasona, years
Mean (standard deviation) 43.7 (17.8) 53.1 (18.2) 48.1 (18.5)
Range  1–82 6–90 1–90
Female,  n (%) 74 (37.0) 70 (40.0) 144 (38.4)
Time  since transplantation at beginning of analyzed season, n (%)
0–30  days 2 (1.0) 0 2 (0.5)
31–90  days 5 (2.5) 6 (3.4) 11 (2.9)
91–180  days 1 (0.5) 6 (3.4) 7 (1.9)
>180  days or before transplantation 192 (96.0) 163 (93.1) 355 (94.7)
Organ  transplant rejection during season, n (%)
Kidney 89 (44.5) 109 (62.3) 198 (52.8)
Liver  19 (9.5) 12 (6.9) 31 (8.3)
Lung  4 (2.0) 5 (2.9) 9 (2.4)
Heart  9 (4.5) 10 (5.7) 19 (5.1)
Pancreas  0 (0) 1 (0.6) 1 (0.3)
Kidney  and liver 0 (0) 1 (0.6) 1 (0.3)
Heart  and lung 0 (0) 1 (0.6) 1 (0.3)
Unspeciﬁedb 79 (39.5) 36 (20.6) 115 (30.7)
≥1  transplant rejection episode before season of interestc, n (%) 5 (2.5) 11 (6.3) 16 (4.3)
Number  of organ transplantations received during season, n (%)
0  158 (79.0) 135 (77.1) 293 (78.1)
1  36 (18.0) 33 (18.9) 69 (18.4)
2  6 (3.0) 7 (4.0) 13 (3.5)
Subjects  reporting cancer/malignancies, n (%) 12 (6.0) 13 (7.4) 25 (6.7)
Reasons  for end of follow-up other than end of season, n (%)
Died 10 (5.0) 15 (8.6) 25 (6.7)
End  of CPRD follow-up 7 (3.5) 3 (1.7) 10 (2.7)
CPRD, Clinical Practice Research Datalink; SOT, solid organ transplant; TIIV, trivalent inactivated inﬂuenza vaccine.
a Season started 1 September 2006, 2007 or 2008.
b The code for transplant rejection was a general code without any organ speciﬁed.
c 180-day period before start of season.
Fig. 2. Subjects included in self-controlled case-series (SCCS) analyses of each inﬂuenza season. Some subjects contributed to several seasons. Some subjects were exposed
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n  season 2006/07 and was excluded. HES, Hospital Episode Statistic; SOT, solid org
For season 2006/07, the RI of rejection of any organ, adjusted for
ime since transplantation, was 0.74 (95% CI: 0.24–2.28) and 0.58
95% CI: 0.24–1.38) during the 30-day and 60-day risk periods after
accination, respectively (Fig. 4). Corresponding RIs for the 2007/08
eason were 1.21 (95% CI: 0.55–2.64) and 1.31 (95% CI: 0.69–2.48)
nd, for the 2008/09 season, 0.99 (95% CI: 0.43–2.28) and 0.64 (95%
I: 0.31–1.33) (Fig. 4). In the pooled seasons analyses, results weres such in the SCCS analyses because transplantation was after vaccination or they
ve a follow-up that included 1 September. b One subject received two doses of TIIV
nsplantation.
consistent with the separate season analyses, with RIs of 1.01 (95%
CI: 0.58–1.76) and 0.88 (95% CI: 0.56–1.38) during the 30-day and
60-day risk periods after vaccination, respectively (Fig. 4).Similar results were observed in a sensitivity analysis using the
standard SCCS method; for each season, 95% CIs included 1 and
upper limits remained below 3 within the 30-day and 60-day risk
periods (Fig. 4). Results from the sensitivity analyses of data pooled
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Fig. 3. Subjects included in the SCCS analyses of data pooled from all three inﬂuenza
seasons. Each subject contributed to only one season, the ﬁrst with an exposure to
TIIV or with an effect of ‘time since transplantation’. Some subjects were exposed to a
TIIV during the season but were not considered as such in the SCCS analyses because
transplantation was after vaccination or they were censored at a second rejection
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2efore vaccination. a To be eligible, subjects had to have a follow-up that included
 September. HES, Hospital Episode Statistic; SCCS, self-controlled case-series; SOT,
olid organ transplantation; TIIV, trivalent inactivated inﬂuenza vaccine.
rom all three seasons were consistent with those from the individ-
al season analyses, with 95% CI upper limits below 2 (Fig. 4).
.2.2. Analyses further adjusted for cancer/malignancies
In multivariate analyses that included other covariates in addi-
ion to time since transplantation, RI could be computed for
ancer/malignancies only, due to the low number of exposed sub-
ects (fewer than ﬁve) for other covariates (bacterial infections and
hronic viral infections). For seasons 2006/07, 2007/08, 2008/09
nd pooled seasons, 75, 81, 93 and 210 cases, respectively, con-
ributed to the analyses. The number of subjects who  had received
 TIIV was 54 in season 2006/07, 55 in 2007/08, 72 in 2008/09 and
52 in the pooled seasons. The RI of transplant rejection of any
rgan during the 30-day and 60-day risk periods after vaccination,
djusted for time since transplantation and cancer/malignancies
as 0.79 (95% CI: 0.25–2.49) and 0.63 (95% CI: 0.26–1.51), respec-
ively, for season 2006/07, 1.29 (95% CI: 0.59–2.85) and 1.43 (95%
I: 0.75–2.72) for season 2007/08 and, 0.99 (95% CI: 0.43–2.28) and
.64 (95% CI: 0.31–1.32) for season 2008/09 (Fig. 4). For pooled
easons, the RIs during the 30-day and 60-day risk periods after vac-
ination were 1.06 (95% CI: 0.61–1.84) and 0.92 (95% CI: 0.59–1.45)
espectively.
.2.3. Analyses restricted to kidney transplant rejection
When transplant rejections were classiﬁed by organ, the num-
er of cases was sufﬁcient for a separate analysis of kidney
ransplanted patients only. For seasons 2006/07, 2007/08, 2008/09
nd pooled seasons, 49, 57, 63 and 144 kidney rejection cases were
onsidered, respectively, of whom 36, 40, 47 and 98 had received TIIV. The RI of kidney rejection during the 30-day risk period
as 0.59 (95% CI: 0.13–2.63), 1.28 (95% CI: 0.52–3.15), 0.98 (95%
I: 0.34–2.80) and 0.91 (0.44–1.87) in seasons 2006/07, 2007/08,
008/09 and pooled seasons, respectively (Fig. 4). Corresponding34 (2016) 3598–3606 3603
RIs during the 60-day risk period were 0.50 (95% CI: 0.16–1.60),
0.82 (95% CI: 0.36–1.86), 0.42 (95% CI: 0.15–1.21) and 0.59 (95% CI:
0.32–1.08), respectively.
3.2.4. Analyses restricted to patients with no previous transplant
rejections
A separate analysis was performed for the group of subjects
who did not experience any rejections within 6 months before the
start of the season (i.e. 1 September). In seasons 2006/07, 2007/08,
2008/09 and pooled seasons, 65, 75, 78 and 204 cases were consid-
ered, respectively, of which 47, 52, 58 and 143 had received a TIIV.
The RI of SOT rejection during the 30-day risk period was  0.66 (95%
CI: 0.19–2.33), 1.10 (95% CI: 0.47–2.55), 1.01 (95% CI: 0.41–2.49)
and 1.04 (95% CI: 0.59–1.84) in seasons 2006/07, 2007/08, 2008/09
and pooled seasons, respectively. RIs during the 60-day risk period
remained within the same range and all 95% CIs included 1, with
upper limits below 3 for individual seasons and below 2 for the
pooled seasons (Fig. 4).
4. Discussion
Although transplant recipients remain a high priority group for
annual seasonal inﬂuenza vaccination in many national inﬂuenza
vaccination programmes, little is known about the safety proﬁle
with regards to risk of transplant rejection following TIIV adminis-
tration. In addition, epidemiological data produced during the 2009
inﬂuenza pandemic have conﬁrmed that SOT patients remain at
high risk of inﬂuenza-associated complications, namely viral and
bacterial pneumonia, hospitalization and even death [26,27].
Recent papers assessed the association between monovalent
pandemic inﬂuenza vaccination and the occurrence of transplant
rejection focusing on the 2009/2010 pandemic inﬂuenza season
[13,28], but none has investigated such an association focusing on
TIIVs. It was  therefore important to formally assess the risk of SOT
rejection associated with seasonal TIIVs in a pharmacoepidemiol-
ogy study.
We therefore assessed the risk of transplant rejection among
SOT recipients following vaccination with seasonal TIIVs in England
throughout three consecutive inﬂuenza seasons using a self-
controlled case-series method.
In the analyses adjusted for time since transplantation, over 200
subjects experienced at least one transplant rejection in any of the
seasons, of whom approximately 70% had received TIIVs. There was
no evidence of an increased risk of SOT rejection within 30 or 60
days after TIIV vaccination, with 95% CIs of RI estimates including
1 and upper limits not exceeding 3 for separate inﬂuenza seasons
and below 2 where seasons were pooled. Analyses that took into
account potential confounders (malignancies or lack of rejection
episodes within 180 days before each season) were consistent with
these results. The most common transplanted organ was  the kid-
ney; a separate analysis restricted to kidney recipients showed no
increased risk of kidney rejection following vaccination with TIIVs.
A strength of this study was the use of CPRD and linked HES
inpatient data. The CPRD has been extensively used in phar-
macoepidemiology research, with data internally and externally
validated for various outcomes [29]. Use of HES inpatient infor-
mation maximized the likelihood of capturing SOT rejections, an
outcome most likely clinically managed in hospital settings. In
the initial identiﬁcation of transplanted patients in the CPRD,
a high proportion (93%; data not shown) had a HES linkage
available, which conﬁrmed the appropriateness of this approach.
In addition, since the HES uses a standardized coding system
(ICD-10 clinical and OPCS-4 procedural coding), consistent infor-
mation was  ensured across the study population [19]. Also, to
account for heterogeneity across inﬂuenza seasons arising from the
3604 G. Dos Santos et al. / Vaccine 34 (2016) 3598–3606
Fig. 4. Relative incidence (RI) of SOT rejection 30 days (A) or 60 days (B) after receiving a TIIV in each inﬂuenza season. Calculated using a modiﬁed SCCS method, in which
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he  total analysis population; Nex, number of TIIV-exposed subjects; SCCS, self-con
ominant circulating virus strains [30], the virulence of speciﬁc
trains, as well as WHO  recommendations on TIIV strain compo-
ition [21], three consecutive seasons were considered separately
nd in pooled analyses. This allowed us to assess the risk, tak-
ng into account potential variability from one inﬂuenza season
o another, and to evaluate the overall risk using a more com-
rehensive approach. Indeed, in Europe, while vaccine strains
ere well matched to circulating strains in 2006/2007, the twohich subjects were not censored for further rejections. Ntot, number of subjects in
d case-series; TST, time since transplantation.
subsequent seasons (2007/2008 and 2008/2009) were charac-
terized by a sub-optimal match between vaccine strains and
circulating strains, especially for type B viruses [30]. This is of par-
ticular importance to this study given the fact that natural infection
caused by inﬂuenza is considered a major independent risk factor
for transplant rejection [9].
Another strength of the study included the use of the SCCS
method, which is case-based and inherently adjusts for ﬁxed
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[1] Kumar D, Blumberg EA, Danziger-Isakov L, Kotton CN, Halasa NB, Ison MG,  et al.
Inﬂuenza vaccination in the organ transplant recipient: review and summary
recommendations. Am J Transplant 2011;11:2020–30.G. Dos Santos et al. / Va
onfounders such as gender, genetic predisposition, health and
ocio-economic status, healthcare-seeking behaviour and access
o healthcare, while controlling for indication bias. In the present
tudy, as vaccination with TIIVs could not be assumed to be fully
ndependent of transplant rejection, a modiﬁed SCCS method was
sed [14], in which only the ﬁrst SOT rejection was  included for
ach subject. In sensitivity analyses, risk estimates were also calcu-
ated using the standard SCCS method [23], in which subjects were
ot censored at subsequent rejections. The results were consistent
ith those calculated using the modiﬁed SCCS method.
A potential limitation of this study was the lack of complemen-
ary information on clinical events or conditions that may  inﬂuence
OT rejection, such as viral/bacterial infection, underlying medical
onditions, non-compliance with immunosuppressive treatment,
iabetes and timing of antiviral therapy [1,2,9]. To overcome this
imitation, for all eligible subjects experiencing a transplant rejec-
ion in the study period, standardized questionnaires were sent
o GPs in order to gather complementary medical history infor-
ation. However, these were returned for less than a quarter of
ubjects with a record of transplant rejection in the CPRD during
he period of interest, of whom fewer than half were identiﬁed by
Ps and reported in the questionnaires as having a SOT rejection,
nd there was a lack of useful complementary information. Since
his suggested that SOT rejection was under-reported and under-
ocumented in primary care records, the HES inpatient database
as used as the sole data source to capture transplant rejection
pisodes.
Determining the risk period was another challenge, given that
ittle is known about the potential mechanism and duration of
ffect of inﬂuenza vaccination on the immune response that could
heoretically be associated with SOT rejection. Two risk periods
ere considered to evaluate the association between seasonal
nﬂuenza vaccination and SOT rejection. A 30-day risk period was
sed based on the latency period of reported spontaneous rejection
vents among subjects who received PandemrixTM and the most
ommon risk period following other exposures such as infection
3]. Using a longer risk period (60-day), estimates remained within
he same range as those for the 30-day risk period. Further study
imitations included the lack of case adjudication to verify the medi-
al history of transplanted patients or the inability to fully assess the
ecent effect of time since transplantation since most subjects had
eceived their organ at least 180 days before the inﬂuenza season
tart. In addition, the effect of previous rejections and risk estimates
or organ rejections other than the kidney could not be computed
ecause of low numbers of subjects who experienced rejections
ithin six months before the start of any season.
Furthermore, there was not enough detail recorded in the CPRD
o perform an analysis by TIIV brand. However, seasonal vaccines
re manufactured using similar processes and all contain the same
trains as per WHO  annual recommendations. Although inﬂuenza
iruses included in cell-based vaccines are grown in cultured cells
f mammalian origin rather than hens’ eggs, cell-based vaccines are
imilar to egg-based inﬂuenza vaccines. Therefore, we can reason-
bly conclude that the results reﬂect the overall “average” safety
roﬁle of TIIVs used during the three inﬂuenza seasons.
In conclusion, we found no evidence of an increased risk of
OT rejection following vaccination with TIIVs in three consecu-
ive inﬂuenza seasons using the SCCS method. Although additional
esearch is needed to determine formally if the ﬁnding in renal
ransplant recipients can be extended to other SOT subgroups as
ell as to all TIIV brands, our study presents reassuring evidence of
he safety proﬁle of TIIVs when administered to SOT recipients. The
esults provide quantitative safety information for healthcare pro-
essionals, policy makers and recommendation bodies and support
urrent recommendations to vaccinate this high-risk population
early in order to prevent inﬂuenza and related complications.34 (2016) 3598–3606 3605
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